Deutsche Bank Ag\ Aravive, Inc. Transaction History

Deutsche Bank Ag\

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 04, 2021	SELL	$3.67 - $5.8 $381 - $603	-104 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$4.65 - $6.42 $39,808 - $54,961	-8,561 Reduced 98.8%	104 $1,000
Q1 2021 May 13, 2021	SELL	$5.11 - $9.24 $3,755 - $6,791	-735 Reduced 7.82%	8,665 $0
Q4 2020 Feb 16, 2021	BUY	$4.36 - $6.51 $10,965 - $16,372	2,515 Added 36.53%	9,400 $54,000
Q3 2020 Nov 12, 2020	BUY	$4.7 - $12.06 $3,064 - $7,863	652 Added 10.46%	6,885 $32,000
Q2 2020 Aug 13, 2020	BUY	$5.18 - $14.81 $32,286 - $92,310	6,233 New	6,233 $72,000
Q1 2019 May 15, 2019	SELL	$3.35 - $8.27 $75,194 - $185,628	-22,446 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.23 - $8.7 $72,500 - $195,280	22,446 New	22,446 $78,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.